| abstract |
Novel pyrimido compounds of formula (I), wherein R 1 to R 9 are as defined herein, are selective inhibitors of both KDR and FGFR kinases and are selective for LCK. The compounds and their pharmaceutically acceptable salts are proliferative inhibitors useful in the treatment or control of solid tumors, especially breast, colon, lung and prostate tumors. Also disclosed are pharmaceutical compositions containing the compounds and their use for the treatment of cancer. |